Exceptionally long-lasting response to dabrafenib plus trametinib treatment in a patient with lung adenocarcinoma harboring the BRAF V600E mutation with high expression of PD-L1: A case report.

Abstract excerpt

We present a patient with lung adenocarcinoma showing high PD-L1 expression and BRAF V600E mutation, who achieved a remarkable long-term response to the combination therapy of dabrafenib and trametinib (DT treatment) after disease progression on immunotherapy. This case may provide an opportunity for clinicians to consider the order of administration of immunotherapy and molecular targeted therapy for BRAF...

Topics

• Humans
• Proto-Oncogene Proteins B-raf
• B7-H1 Antigen
• Adenocarcinoma of Lung
• Lung Neoplasms
• Mutation
• Imidazoles
• Oximes
• Pyridones
• Pyrimidinones